Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

USC School of Medicine to host the first World Congress of Ultrasound in Medical Education

Ultrasound is a valuable tool that allows doctors to diagnose and treat patients quickly and accurately. It's been around for decades, but there has been revolutionary change in the technology in recent years, making the machines smaller, cheaper and smarter.

21 Jan 2011

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.

10 Jan 2011

New genetic alteration predisposes individuals to Cowden syndrome

Researchers have identified a new genetic alteration that predisposes individuals to Cowden syndrome, a rare disorder that is characterized by high risks of breast, thyroid and other cancers, according to preliminary research published in the December 22/29 issue of JAMA.

21 Dec 2010

Head, neck radiation exposure increases thyroid cancer in children

When children are exposed to head and neck radiation, whether due to cancer treatment or multiple diagnostic CT scans, the result is an increased risk of thyroid cancer for the next 58 years or longer, according to University of Rochester Medical Center research.

17 Dec 2010

NCI initiates crolibulin/cisplatin combination Phase II trial in anaplastic thyroid cancer

EpiCept Corporation today announced that the National Cancer Institute (NCI) has initiated a Phase II trial with crolibulinTM (EPC2407). The trial will assess the drug's efficacy and safety in combination with cisplatin in patients with anaplastic thyroid cancer (ATC). CrolibulinTM is a vascular disruption and apoptosis inducing agent that has demonstrated potent anti-tumor activity in both preclinical and early clinical studies.

15 Dec 2010

AstraZeneca announces FDA Advisory Committee meeting outcome for vandetanib NDA

AstraZeneca today announced the outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee meeting to discuss the New Drug Application (NDA) for AstraZeneca's investigational drug, vandetanib, for the treatment of patients with unresectable (non-operable) locally advanced or metastatic medullary thyroid cancer (MTC).

2 Dec 2010

Research may lead to new treatment strategies for Graves' disease

Researchers at the National Institutes of Health have identified a compound that prevents overproduction of thyroid hormone, a finding that brings scientists one step closer to improving treatment for Graves' disease.

2 Dec 2010

Pfizer awards $2.1 million grant to NCCN to evaluate axitinib in solid tumors

The National Comprehensive Cancer Network has been awarded a $2.1 million grant from Pfizer to develop a program to scientifically evaluate and define the clinical activity of axitinib in various tumor types.

1 Dec 2010

New genomic approach to evaluate suspicious thyroid nodules

Doctors at the University of Colorado School of Medicine were concerned recently when they found a nodule in the thyroid of a 64-year-old Colorado man. They extracted cells from the nodule, hoping to determine whether the man had cancer. But the biopsy results were inconclusive.

24 Nov 2010

OXiGENE updates data on FALCON trial for non-small cell lung cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT(TM) (CA4P) in patients with non-small cell lung cancer (NSCLC).

19 Nov 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Exelixis, Inc. today reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Study discovers health care gap in treating young patients with thyroid cancer

Thyroid cancer is the third most common malignancy in children, and the incidence is rising approximately one percent per year. Now a new analysis published in the October issue of Annals of Surgical Oncology indicates that although the proportion of young patients undergoing total thyroidectomy increased by 34 percent between 1985 and 2007, a variety of hospital and patient factors—including disparities in access to surgeons and state-of-the-art care—affect whether a child actually receives this procedure or another less extensive operation.

16 Nov 2010

Dr Sartori’s contentious alternative therapy: inquest date set

The Medical Practitioner's Board of Western Australia is looking into the case of a doctor and her role in an alternative cancer therapy program. Five cancer patients have died after apparently being given industrial solvents and dangerous minerals as a part of an alternative therapy program by Alexandra Boyd, a well-known Mosman Park breast cancer specialist. She along with two registered nurses administered the concoctions to the people in question.

1 Nov 2010

OXiGENE announces ZYBRESTAT Phase 2/3 study results at ESMO Congress

OXiGENE, a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that an ongoing analysis of positive results reported earlier from a randomized, controlled, Phase 2/3 study of ZYBRESTAT (fosbretabulin, CA4P) were presented today at the 35th European Society of Medical Oncology (ESMO) Congress in Milan, Italy by Julie Ann Sosa, M.D., F.A.C.S., of Yale University.

11 Oct 2010

Louise A. Villejo recognized with 2010 Julie and Ben Rogers Award for Excellence in Education

Louise A. Villejo, executive director of the Patient Education Office at The University of Texas MD Anderson Cancer Center, is the recipient of the 2010 Julie and Ben Rogers Award for Excellence in Education.

7 Oct 2010

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 national research and training grants totaling $46,633,000 to 70 institutions nationwide in the first of two grants cycles for 2011.

7 Oct 2010

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.

23 Sep 2010

Lixisenatide experimental diabetes drug shows potential in trial

Researchers at the R&D section of drug maker Sanofi Aventis have confirmed this Monday that a study of its experimental diabetes drug showed better blood sugar control than placebo.

21 Sep 2010

Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

USC School of Medicine to host the first World Congress of Ultrasound in Medical Education

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

New genetic alteration predisposes individuals to Cowden syndrome

Head, neck radiation exposure increases thyroid cancer in children

NCI initiates crolibulin/cisplatin combination Phase II trial in anaplastic thyroid cancer

AstraZeneca announces FDA Advisory Committee meeting outcome for vandetanib NDA

Research may lead to new treatment strategies for Graves' disease

Pfizer awards $2.1 million grant to NCCN to evaluate axitinib in solid tumors

New genomic approach to evaluate suspicious thyroid nodules

OXiGENE updates data on FALCON trial for non-small cell lung cancer

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis reports interim data from phase 2 RDT trial for epithelial ovarian cancer

Study discovers health care gap in treating young patients with thyroid cancer

Dr Sartori’s contentious alternative therapy: inquest date set

OXiGENE announces ZYBRESTAT Phase 2/3 study results at ESMO Congress

Louise A. Villejo recognized with 2010 Julie and Ben Rogers Award for Excellence in Education

American Cancer Society awards 94 national research, training grants to 70 institutions nationwide

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

Lixisenatide experimental diabetes drug shows potential in trial

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Thyroid Cancer News and Research

Latest Thyroid Cancer News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in